Graft Versus Host Inhibition. IX. The Therapeutic Potential of Combined Fetal Liver and Thymus Cells as a Universal Hematopoietic Stem Cell Source for Transplantation.
Abstract
The major accomplishment under this contract was the development and testing of a treatment model using mice to evaluate transplantation of liver and thymus cells from immunologically immature (fetal) donors as a source of hematopoietic stem cells. The following observations were made: (1) Fetal liver cells can be used as a source of hematopoietic stem cells without the complication of acute graft-versus-host disease; (2) Recovery from radiation injury was dependent on the dose of fetal liver cells transplanted; (3) Transplanting very small numbers of fetal thymus cells, in addition to liver cells, had a significant and salutary effect on recovery from radiation injury in some strain combinations, but not in others; (4) Transplantation of fetal liver cells from histoincompatible unrelated donors resulted in less delayed secondary disease mortality than did bone marrow transplants from histocompatible unrelated donors; (5) Cell yields from human embryonic tissue increased exponentially with age, and the liver:thymus ratio was 35.4:1, and (6) Fetal liver + or - thymus cells promoted recovery in lethally irradiated adult mice when given in a cell dose per kg body weight comparable to that from a human fetus at 14 weeks embryonation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 18, 1978
- Accession Number
- ADA049151
Entities
People
- Mortimer M. Bortin
Organizations
- Mount Sinai Hospital